ArticleJournal of hepatology2026
Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD.
Article in Journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients · 2026Review
- CHAIN Cohort: Prospective Multicenter Study of MASLD With Serial Liver Stiffness Assessments in Cardiovascular Care.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND &
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by cardiometabolic risk factors (CMRFs). Treatment of CMRFs is the cornerstone of MASLD management, yet other than weight loss, the association between changes in CMRFs and changes in liver-related measures is not defined. This study aimed to characterize these longitudinal associations using non-invasive measurements of hepatic fibrosis and steatosis.
methodsAdult participants from the NASH CRN prospective study with biopsy-proven MASLD and at least two sequential vibration-controlled transient elastography (VCTE) exams (≥1 year apart) were included. Annual changes in CMRF parameters were compared against annual changes in liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) using adjusted mixed-effects multinomial logistic regression. The primary outcome was LSM change ≥25% (compared to a reference group of no change, or <25% LSM change), while secondary outcomes were CAP change ≥30% and changes in histologic grading of steatohepatitis or fibrosis.
resultsA total of 1,417 participants were included (mean age 52 years, 38% male, 82% Caucasian). Annual worsening in all CMRFs (except triglycerides and HDL) was associated with LSM worsening (17% greater risk per 1% increase in hemoglobin A1c; 24% greater risk per 5% increase in weight). Improvements in all CMRFs were associated with LSM improvement (32% greater chance per 1% decrease in hemoglobin A1c; 27% greater chance per 5% decrease in weight). Similar associations were observed for changes in CAP.
conclusionsAnnual changes in CMRFs were associated with clinically relevant changes in LSM, CAP, and liver histology. These findings suggest that treatment of metabolic comorbidities is associated with the trajectory of MASLD. IMPACT AND IMPLICATIONS: Guideline-directed treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) is focused on optimal treatment of cardiometabolic comorbidities, but there is limited evidence on the association between outcomes of this treatment and changes in markers of liver health. The results of this study demonstrate that longitudinal changes in these cardiometabolic parameters, particularly those associated with body weight, blood pressure, and glucose intolerance, are associated with both increases and decreases in liver stiffness measurements that represent clinically meaningful changes in liver health. These results are broadly relevant to the care of individuals with MASLD, as these results can provide meaningful treatment targets for guideline development and treating clinicians, as well as provide feasible goals for impacted individuals with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.